fda import alert green list glp-1 semaglutide tirzepatide 2025 🚨Big shifts in the GLP- 1 landscape🚨 FDA Issues Import Alert on

McMurray reports payments to his institution for work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardurion, Cytokinetics, Dal-Cor, GSK, lonis, KBP Biosciences, Novartis, Pfizer, and Theracos, as well as personal payments from Abbott, Alkem Metabolics, AstraZeneca, Boehringer Ingelheim, Cardurion, Eris Lifesciences, Hikma, lonis, Lupin, Novartis, ProAdWise Communications, and Sun Pharmaceuticals

In this episode of Peptides Explained , we break down: What MOTS-C is and how its produced How it activates AMPK, the bodys metabolic master switch Why its being studied as a potential exercise mimetic Its effects on insulin sensitivity and glucose metabolism What the animal research shows vs

-1.1% using dulaglutide in the SUSTAIN-7 trial

References FDA approval label for Semaglutide FDA approval label for Tirzepatide Jensen TL, Brnden A, Karstoft K, Sonne DP, Christensen MB

A statistical analysis of three double-blind studies